The bill would mandate that the government negotiate with drug makers about the price of insulin, both in the Medicare program and for the open insurance market. It also includes many other mechanisms intended to lower the price of insulin and other drugs.
-T1D Exchange staff On September 23rd, T1D Exchange will hold its annual meeting at the Royal Sonesta in Cambridge, Massachusetts. The theme of this year’s meeting is data–and the organization’s commitment to use it alongside collaboration to improve outcomes for individuals with type 1 diabetes. In the keynote address, “The Evolution of Real-World Evidence in […]
The two separate collaborations will soon allow the companies to make more readily available blood sugar readings and insulin dosing information across more diabetes devices, apps, and platforms.
Four insurers have introduced a cap on monthly insulin costs, but the federal government’s move to change regulations around high-deductible insurance plans may have the biggest long-term impact.